AACR 2026: AI Pathology & Oncolytic Virus Spark Interest

Key Takeaways

• Path-IO, a biology-guided AI pathomics framework, outperformed PD-L1 expression in stratifying immunotherapy risk in metastatic NSCLC, achieving C-index of 0.63 for overall survival versus PD-L1's 0.58, with further improvement to 0.75 when combined with radiomics and clinical data.
• VCN-01 (zabilugene almadenorepvec), an oncolytic adenovirus, demonstrated improved tumor responses and potential survival benefits in first-line metastatic pancreatic cancer when combined with gemcitabine and nab-paclitaxel, with strongest efficacy in patients with liver metastases.
• Neutrophil extracellular traps (NETs) actively drive colorectal cancer metastasis and necrosis, with genetic and pharmacologic NET inhibition reducing intratumoral necrosis and metastatic burden in preclinical models and clinical evidence.
• Revolution Medicines' zoldonrasib demonstrated strong clinical data for KRAS-driven lung cancers, advancing targeted therapy options for this historically difficult-to-treat population.

AACR 2026 Convenes in San Diego with AI Pathology and Oncolytic Virus Breakthroughs

The American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17–22 in San Diego, California, showcased pivotal advances in cancer treatment and diagnosis, with particular emphasis on artificial intelligence-driven pathology models and oncolytic virus immunotherapy. Two presentations dominated early discussion: Path-IO, a machine learning framework that predicts immunotherapy response in non-small cell lung cancer (NSCLC) patients, and Theriva Biologics' Phase 2b data on VCN-01 (zabilugene almadenorepvec) combined with standard chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC). These presentations underscore the conference's focus on precision oncology, biomarker-driven patient stratification, and immune-mediated cancer treatment mechanisms.

Event Significance and Context

AACR 2026 attracted thousands of oncologists, researchers, and industry leaders to discuss emerging clinical trial data, novel therapeutic targets, and translational science. The meeting highlighted a shift toward AI-enabled diagnostics and combination immunotherapy approaches, reflecting the broader oncology field's movement away from one-size-fits-all cancer treatment toward personalized medicine. Key themes included biomarker discovery, immune checkpoint modulation, and the role of the tumor microenvironment in treatment response—areas where both computational pathology and oncolytic viruses are reshaping clinical practice.

Path-IO: AI-Driven Pathomics for NSCLC Immunotherapy Stratification

Researchers from UT MD Anderson Cancer Center presented Path-IO, a biology-guided artificial intelligence framework designed to predict immunotherapy response in patients with metastatic NSCLC. The model analyzes routine pathology slides to stratify patients into higher- and lower-risk groups, addressing a critical unmet need in precision oncology: identifying which lung cancer patients will benefit most from immune checkpoint inhibitor (ICI) therapy.

Clinical Performance and Biomarker Superiority: Path-IO demonstrated superior discrimination compared to PD-L1 expression alone. In the discovery cohort and external validation set, Path-IO achieved a C-index of 0.63 for overall survival (OS) and 0.58 for progression-free survival (PFS), outperforming PD-L1's C-index of 0.58 (OS) and 0.57 (PFS). Patients stratified into the high-risk group showed greater than twofold higher risk of death or disease progression, enabling clinicians to identify patients who may require alternative or intensified treatment strategies.

Multimodal Integration Enhances Predictive Power: When Path-IO was combined with radiomics features and clinical data, predictive accuracy improved substantially to a C-index of 0.75 for OS and 0.70 for PFS. This multimodal approach leverages complementary information from pathology images, radiographic imaging, and patient characteristics, demonstrating that AI-driven cancer treatment decisions benefit from integrated data sources. The model correlated with immune profiling and multiplex imaging findings, providing mechanistic insight into the pathologic features driving immunotherapy response.

Presentation Details: The Path-IO data were presented on April 20, 2026, as part of the biomarker and risk stratification track. While the discovery and validation results are encouraging, prospective clinical trials are needed to confirm Path-IO's utility in real-world clinical practice and to establish its role in treatment selection algorithms.

VCN-01 in Metastatic Pancreatic Cancer: Oncolytic Virus Immunotherapy Data

Theriva Biologics (NASDAQ: TOVX) presented Phase 2b data from the VIRAGE trial evaluating VCN-01 (zabilugene almadenorepvec), an oncolytic adenovirus engineered to degrade tumor stroma and activate anti-tumor immunity, combined with gemcitabine and nab-paclitaxel in first-line metastatic PDAC. The presentation, led by Dr. Manuel Hidalgo of NYU Langone, highlighted tumor response rates, biomarker correlates, and subgroup analyses supporting the clinical development of this oncolytic virus immunotherapy approach.

Efficacy and Response Data: VCN-01 combination therapy demonstrated improved tumor responses compared to historical controls and standard-of-care chemotherapy alone. Notably, patients with liver metastases showed the strongest clinical benefit, suggesting that the oncolytic virus may preferentially target hepatic disease or that liver-predominant metastatic disease represents a more immunologically permissive microenvironment. Response duration was prolonged in VCN-01-treated patients, and potential survival benefits were observed, though mature overall survival data were not detailed in the conference abstract.

Mechanism and Biomarker Support: The data support an immune-mediated mechanism of action, with VCN-01 degrading tumor-associated stroma (rich in hyaluronic acid and collagen) to enhance immune cell infiltration and activation. Biomarker analyses correlated treatment response with immune activation signatures, reinforcing the rationale for combining oncolytic virus therapy with chemotherapy to create a synergistic anti-tumor immune response. VCN-01 has been tested in more than 140 patients across multiple cancer types, establishing a broad clinical development program.

Regulatory Path and Next Steps: The VIRAGE Phase 2b data are FDA and EMA-aligned for Phase 3 clinical trial initiation, with plans for multiple-dose VCN-01 regimens. The poster presentation occurred on April 20, 2026, from 2–5 PM PDT, providing attendees with detailed efficacy, safety, and biomarker data to inform future clinical trial design and patient selection strategies.

Key Presentations and Data Highlights from AACR 2026

Neutrophil Extracellular Traps (NETs) in Colorectal Cancer Metastasis: Researchers presented evidence that neutrophil extracellular traps actively drive tumor necrosis and metastatic progression in colorectal cancer (CRC), challenging the traditional view of necrosis as a passive process. Using preclinical organoid models harboring APC loss, KRAS G12D, TP53 loss, and SMAD4 loss mutations—mimicking human CRC—investigators demonstrated that genetic and pharmacologic NET inhibition reduced intratumoral necrosis and metastatic burden. Single-cell RNA sequencing and spatial transcriptomics identified NET-rich microenvironments and a specific neutrophil subset as potential biomarkers for patient stratification in future clinical trials.

Revolution Medicines' Zoldonrasib in KRAS-Driven Lung Cancer: Revolution Medicines presented strong clinical trial data on zoldonrasib, a selective KRAS inhibitor targeting KRAS-driven non-small cell lung cancers. The presentation on Day 1 of the conference highlighted efficacy and safety data from ongoing clinical trials, building on prior evidence and reinforcing zoldonrasib's potential as a precision oncology agent for this historically difficult-to-treat patient population. KRAS mutations occur in approximately 30% of lung adenocarcinomas and have long been considered undruggable; zoldonrasib represents a significant advance in targeted cancer treatment for KRAS-mutant disease.

Memorial Sloan Kettering Cancer Center Highlights: MSKCC researchers presented multiple clinical and translational studies, including promising early-stage trial results for HER2-driven rectal cancer and KRAS-driven pancreatic cancer therapies. An mRNA cancer vaccine for pancreatic cancer showed encouraging Phase 1 results, demonstrating immune activation and clinical benefit in early-stage patients. Additionally, MSKCC investigators presented a novel solid tumor targeting approach that shrank tumors and cleared metastases in preclinical lung, pancreatic, and ovarian cancer models, suggesting potential for future clinical translation.

EBV Persistence and Cancer Risk: A large genetic association study identified 22 genetic variants linked to higher Epstein-Barr virus (EBV) activity and chronic disease risk, including cancer. This framework provides a foundation for understanding viral persistence mechanisms and may inform future cancer prevention and treatment strategies targeting EBV-associated malignancies.

Lung Cancer and Mental Health in EGFR-Mutated Patients: Data presented at AACR 2026 illuminated the demographic and psychosocial burden of EGFR-mutated lung cancer, with 65% of patients being female compared to 49% in non-EGFR-mutated disease and 62% in the general lung cancer population. The presentation highlighted mental health risks and unmet supportive care needs in this growing patient population, underscoring the importance of holistic cancer treatment approaches.

Environmental Risk Factors and Cancer Incidence: Epidemiologic data presented at the conference linked wildfire smoke exposure to increased risk of lung, colorectal, breast, bladder, and blood cancers. This environmental oncology research highlights the role of air quality and climate factors in cancer etiology, with implications for public health policy and patient counseling.

Quanterix Antibody-Drug Conjugate (ADC) Programs: Quanterix presented high-plex multiplex immunofluorescence (mIF) panels for characterizing ADC programs in breast and lung cancer tissues, enabling detailed biomarker analysis and patient stratification. Additionally, the AidaBreast™ multi-omic assay was showcased as a tool for precision breast cancer diagnosis and treatment selection.

AACR Project GENIE and Precision Oncology: AACR Project GENIE, a large-scale genomic data initiative, presented updated data models for precision oncology, facilitating real-world evidence generation and clinical trial matching. This resource supports the broader oncology community's shift toward data-driven cancer treatment decisions.

Market and Investor Implications

The AACR 2026 presentations carry significant implications for pharmaceutical companies, diagnostic firms, and investors focused on precision oncology and immunotherapy. Path-IO's superior performance compared to PD-L1 expression suggests a substantial market opportunity for AI-driven pathology platforms in NSCLC patient stratification. The global digital pathology market is projected to grow significantly as healthcare systems adopt computational pathology tools; Path-IO's clinical validation positions it as a potential standard-of-care biomarker for ICI patient selection.

Theriva Biologics' VCN-01 data advance the clinical development of oncolytic virus immunotherapy, a therapeutic modality with limited approved agents. The Phase 2b efficacy signals and FDA/EMA alignment for Phase 3 suggest potential for regulatory approval and market entry in metastatic PDAC, a disease with poor prognosis and limited treatment options. Investors tracking Theriva Biologics (TOVX) should monitor Phase 3 enrollment and interim efficacy readouts, as positive results could support accelerated approval pathways and expanded indications.

Revolution Medicines' zoldonrasib data reinforce the commercial opportunity in KRAS-targeted therapy, with multiple companies advancing KRAS inhibitors into late-stage clinical trials. The competitive landscape for KRAS-driven cancers is intensifying, and zoldonrasib's clinical trial performance will determine its market positioning and potential peak sales.

The broader AACR 2026 program underscores investor interest in combination immunotherapy approaches, biomarker-driven patient selection, and the integration of AI and machine learning into oncology. Companies developing complementary technologies—such as multiplex immunofluorescence platforms, genomic sequencing assays, and clinical decision support software—are well-positioned to capture value from the precision oncology market expansion.

What to Watch Next

Path-IO Clinical Validation: Prospective clinical trials are needed to confirm Path-IO's utility in real-world practice and to establish its role in treatment selection algorithms for metastatic NSCLC. Regulatory discussions with the FDA regarding biomarker qualification and companion diagnostic development will be critical milestones.

VCN-01 Phase 3 Initiation: Theriva Biologics is expected to initiate Phase 3 clinical trials of VCN-01 in metastatic PDAC in the coming months. Enrollment rates, interim efficacy readouts, and safety data will be key indicators of the program's success and potential for regulatory approval.

Zoldonrasib Competitive Landscape: As multiple KRAS inhibitors advance through clinical development, comparative efficacy and safety data will emerge. Zoldonrasib's performance relative to competing agents will determine its market share and clinical adoption in KRAS-driven lung cancer.

NET-Targeted Therapies: The colorectal cancer NET data may catalyze development of NET-inhibiting agents as combination partners with chemotherapy or immunotherapy. Clinical trials targeting NET formation or function in CRC and other malignancies are anticipated.

mRNA Cancer Vaccines: The encouraging Phase 1 data for mRNA cancer vaccines in pancreatic cancer suggest potential for expansion into Phase 2 trials and combination studies with checkpoint inhibitors or chemotherapy.

Frequently Asked Questions

References

• [1] ReachMD. "AACR Release Highlights Pathomics Model for NSCLC Immunotherapy Response." Accessed April 2026. https://reachmd.com/news/aacr-release-highlights-pathomics-model-for-nsclc-immunotherapy-response/2486773/
• [2] MarketChameleon. "Theriva Biologics VIRAGE Phase 2b VCN-01 AACR 2026." April 20, 2026. https://marketchameleon.com/articles/b/2026/4/20/theriva-biologics-virage-phase-2b-vcn01-aacr-2026
• [3] OncologyTube. "2026 Cancer Breakthroughs: Dr. Joshua Cohen MOASC." Accessed April 2026. https://oncologytube.com/2026-cancer-breakthroughs-dr-joshua-cohen-moasc/
• [4] OncoDaily. "AACR 2026: NETs, CRC Necrosis, Metastasis." April 2026. https://oncodaily.com/oncolibrary/aacr-2026-nets-crc-necrosis-metastasis
• [5] American Association for Cancer Research. "AACR Annual Meeting 2026 Program Guide." https://www.aacr.org/AM26programguide/
• [6] STAT News. "AACR 2026: Strong Data for Revolution Medicines KRAS Drug." April 19, 2026. https://www.statnews.com/2026/04/19/aacr-2026-strong-data-for-revolution-medicines-kras-drug/
• [7] Labiotech.eu. "AACR 2026 Cancer Therapeutics." April 2026. https://www.labiotech.eu/trends-news/aacr-2026-cancer-therapeutics/
• [8] Quanterix. "AACR American Association for Cancer Research Annual Meeting 2026." https://www.quanterix.com/events-conferences/aacr-american-association-for-cancer-research-annual-meeting-2026/